# An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

> **NCT00000935** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 100 (estimated)

## Conditions studied

- End-Stage Renal Disease
- Kidney Transplantation

## Interventions

- **BIOLOGICAL:** Intravenous immune globulin (IVIG)

## Key facts

- **NCT ID:** NCT00000935
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2003-06
- **Final completion:** 2003-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000935, "An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*